Fulgent Genetics Inc (FLGT) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Fulgent Reports Third Quarter 2024 Financial Results

Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280...

Fulgent to Participate in Upcoming Conferences

Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services...

Form 4 - Statement of changes in beneficial ownership of securities

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities